|
|
Post by harleyquinn on Feb 26, 2016 16:05:09 GMT
Getting shorted to @#$%. Any one else in this one? It's pretty quiet over here....
|
|
|
|
Post by hoosier57 on Feb 27, 2016 18:10:30 GMT
Very much still in and accumulating. Sell off due to post earnings, IMO. Chip answered investor concerns and said that over 70 sights are now up and running between Imbark and Imerge trials and all progressing nicely. I really believe that we will be moving forward with the results from Imerge before the results from Imbark because the primary endpoint of transfusion independance may happen faster than the primary end points of Imbark.Chip also indicated during Q/A of the CC, that Janssen may elect to start any additional trials for other indications, ( AML?) before electing continuation from protocols of Imerge or Imbark studies. If and when that happens it, in my book, it will be because all is progressing in good fashion on Imbark and Imerge trials. I believe any additional trials above and beyond Imbark and imerge will be 80/20 cost share Janssen/ Geron. Still got plenty of money on hand, 143 million I believe,more than enough for the trials. Just about the time that I think that there won't be anything to move the needle, we hear of another published report supporting Imetelstat. I am good to be a patient long.
|
|
|
|
Post by harleyquinn on Feb 29, 2016 14:34:20 GMT
Here goes again. Don't like the way this one is being traded lately.
|
|
